Y. Inukai

Impact of primary kidney disease on the effects of empagliflozin in patients with chronic kidney disease: secondary analyses of the EMPA-KIDNEY trial

PK Judge, Natalie Staplin, KJ Mayne et al. · The Lancet Diabetes & Endocrinology · 2023 · 108 citations · Full text

Medicine, Nephrology, Pharmacotherapy +11

Effect of Treating Hyperphosphatemia With Lanthanum Carbonate vs Calcium Carbonate on Cardiovascular Events in Patients With Chronic Kidney Disease Undergoing Hemodialysis

Masafumi Fukagawa, Hideki Hirakata, Tatsuo Kagimura et al. · JAMA · 2021 · 90 citations · Full text

Medicine, Nephrology, Pharmacotherapy +14

Effects of empagliflozin on progression of chronic kidney disease: a prespecified secondary analysis from the empa-kidney trial

Natalie Staplin, Richard Haynes, PK Judge et al. · The Lancet Diabetes & Endocrinology · 2023 · 90 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +14

Changes in expression of T-helper (Th) 1- and Th2-associated chemokine receptors on peripheral blood lymphocytes and plasma concentrations of their ligands, interferon-inducible protein-10 and thymus and activation-regulated chemokine, after antithyroid drug administration in hyperthyroid patients with Graves’ disease

Y. Inukai, Atsushi Momobayashi, Naoto Sugawara et al. · European Journal of Endocrinology · 2007 · 39 citations

Life Sciences, Endocrinology, Immunology +13

The effect of low-dose atorvastatin on circulating monocyte chemoattractant protein–1 in patients with type 2 diabetes complicated by hyperlipidemia

Kohzo Takebayashi, Sachiko Matsumoto, Sadao Wakabayashi et al. · Metabolism · 2005 · 22 citations

Veterinary Medicine, Pharmacology, Pharmacotherapy +10